Which Biden vaccine are y'all getting? The Pfizer is ultra Biden, but I want to buy domestic and help in the Biden led American recovery. Pfizer-BioNTech How well it works: 95% efficacy in preventing COVID-19 in those without prior infection. The researchers report that the vaccine was equally effective across a variety of different types of people and variables, including age, gender, race, ethnicity, and body mass index (BMI)—or presence of other medical conditions. In clinical trials, the vaccine was 100% effective at preventing severe disease. How well it works on virus mutations: So far, the Pfizer-BioNTech vaccine has been found to protect against the variant that was first detected in Great Britain (B.1.1.7), but it may be less effective against the variant first detected in South Africa (B.1.351). Moderna How well it works: 94.1% effective at preventing symptomatic infection in people with no evidence of previous COVID-19 infection. The vaccine appeared to have high efficacy in clinical trials among people of diverse age, sex, race, and ethnicity categories and among persons with underlying medical conditions (although as mentioned above, the efficacy rate drops to 86.4% for people ages 65 and older). How well it works on virus mutations: Some research has suggested that Moderna’s vaccine may provide protection against the B.1.1.7 and B.1.351 variants. Researchers are still studying this. Johnson & Johnson How well it works: 72% overall efficacy and 86% efficacy against severe disease in the U.S. How well it works on virus mutations: This vaccine’s effectiveness has been shown to offer protection against the B.1.1.7 variant. According to the analyses the FDA released in late February, there was 64% overall efficacy and 82% efficacy against severe disease in South Africa, where the B.1.351 variant was first detected. Oxford-AstraZeneca How well it works: AstraZeneca updated its data analysis of its phase 3 trials in March, showing its vaccine to be 76% effective at reducing the risk of symptomatic disease 15 days or more after receiving the two doses, and 100% against severe disease. The company also said the vaccine was 85% effective in preventing COVID-19 in people over 65. The company’s update came a few days after the National Institute for Allergy and Infectious Diseases (NIAID) expressed concern over new data AstraZeneca had submitted in advance of requesting an EUA from the FDA. The NIAID said that data may have included outdated information, which would make its efficacy data incomplete. How well it works on virus mutations: So far it seems to work better against the mutation that emerged in Great Britain than the one that emerged in South Africa. A paper in early February (not yet peer-reviewed) cited 74.6% efficacy against the B.1.1.7 variant. However, the vaccine did not protect as well against mild and moderate cases in people infected with the B.1.351 variant. Therefore, South Africa halted its rollout while scientists continue to study whether the vaccine can prevent severe illness and death in people infected with this variant.
A little more detail from the NEJM.org on Covid variants: New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications TO THE EDITOR: Across the world, there are multiple variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19). SARS-CoV-2 variants have been classified by the Centers for Disease Control and Prevention (CDC) as variants of interest, variants of concern, and variants of high consequence. Three new variants1 that have rapidly become dominant within their countries have aroused concerns: B.1.1.7 (also known as VOC-202012/01), 501Y.V2 (B.1.351), and P.1 (B.1.1.28.1). The B.1.1.7 variant (23 mutations with 17 amino acid changes) was first described in the United Kingdom on December 14, 2020; the 501Y.V2 variant (23 mutations with 17 amino acid changes) was initially reported in South Africa on December 18, 2020; and the P.1 variant (approximately 35 mutations with 17 amino acid changes) was reported in Brazil on January 12, 2021. By February 22, 2021, the B.1.1.7 variant had been reported in 93 countries, the 501Y.V2 variant in 45, and the P.1 variant in 21.1 All three variants have the N501Y mutation, which changes the amino acid asparagine (N) to tyrosine (Y) at position 501 in the receptor-binding domain of the spike protein. The 501Y.V2 and P.1 variants both have two additional receptor-binding–domain mutations, K417N/T and E484K. These mutations increase the binding affinity of the receptor-binding domain to the angiotensin-converting enzyme 2 (ACE2) receptor. Four key concerns stemming from the emergence of the new variants are their effects on viral transmissibility, disease severity, reinfection rates (i.e., escape from natural immunity), and vaccine effectiveness (i.e., escape from vaccine-induced immunity). The 501Y.V2 variant spread rapidly in South Africa, accounting for 11% of the viruses sequenced (44 of 392) in the first week of October 2020, for 60% of those sequenced (302 of 505) in the first week of November 2020, and for 87% of those sequenced (363 of 415) in the first week of December 2020. In Western Cape, a South African province where the 501Y.V2 variant is predominant, a threshold of 100,000 cases of Covid-19 was reached approximately 50% more quickly in the second wave of infection than in the first wave (54 vs. 107 days). The 501Y.V2 variant has been estimated to be 50%2 more transmissible than preexisting variants in South Africa, and B.1.1.7 to be between 43% and 82%3 more transmissible than preexisting variants in the United Kingdom. Hospital admission rates of diagnosed cases and the clinical profile of admitted patients were similar in the first and second waves in Western Cape. However, a preliminary analysis by the National Institute of Communicable Diseases showed that the 501Y.V2 variant was associated with in-hospital mortality that was 20% higher in the second wave in South Africa than in the first wave. This finding was due mainly to the greater transmissibility of this variant, which rapidly overburdened health services and thus compromised timely access to hospital care and the quality of that care. Evidence from the United Kingdom indicates that the B.1.1.7 variant may be associated with a higher risk of death than preexisting variants in the United Kingdom.4Although there is no evidence that antiviral agents and antiinflammatory treatments are any less effective with the emerging variants than with the preexisting variants, treatment with convalescent serum and monoclonal antibodies may not be as effective. With regard to escape from natural immunity, the B.1.1.7 variant showed a modest decrease in neutralization activity, by a factor of 1.5, whereas the 501Y.V2 variant showed complete escape from neutralizing antibodies in 48% of convalescent serum samples (21 of 44) obtained from patients who had previously had Covid-19.5 A serendipitous finding from a vaccine trial in South Africa, in which 31% of the enrolled participants had previously been infected with SARS-CoV-2, was that the incidence of Covid-19, as confirmed on polymerase chain reaction, was 7.9% among seronegative enrollees and 4.4% among seropositive enrollees in the placebo group. This finding indicates that previous infection with preexisting variants may provide only partial protection from reinfection with the 501Y.V2 variant. Table 1. Summary Results on SARS-CoV-2 Vaccine Trial Efficacy and Viral Neutralization of the B.1.1.7, P.1, and 501Y.V2 Variants, as Compared with Preexisting Variants. With regard to escape from vaccine-induced immunity, the B.1.1.7 variant showed modest decreases in neutralizing activity in serum samples obtained from vaccinated persons (Table 1). The serum neutralizing activity for the 501Y.V2 variant among vaccinated persons was lower by a factor of 1.6 to 8.6 for the BBIBP-CorV vaccine, the BNT162b2 vaccine, and the mRNA-1273 vaccine but was lower by a factor of up to 86, including complete immune escape, for the AZD1222 vaccine (Table 1). Neutralizing activity for the P.1 variant among vaccinated persons was lower by a factor of 6.7 for the BNT162b2 vaccine and by a factor of 4.5 for the mRNA-1273 vaccine (Table 1). The clinical relevance of the lower neutralization activity for either mild or severe Covid-19 is not clear, but efficacy in clinical trials was lower for all three vaccines tested in the midst of transmission of the 501Y.V2 variant in South Africa than efficacy in trials conducted in countries with preexisting variants. Efficacy was higher by a factor of 3.2 with the AZD1222 vaccine in the United Kingdom and Brazil than in South Africa (70% vs. 22%), higher by a factor of 1.8 with the NVX-CoV237 vaccine in the United Kingdom than in South Africa (89% vs. 49%), and higher by a factor of 1.3 with the Ad26.COV2.S vaccine in the United States than in South Africa (72% vs. 57%). The emergence of these three new variants of concern highlight the importance of vigilance with genomic surveillance for the early identification of future variants. Recently, two more SARS-CoV-2 variants, B.1.427 and B.1.429, which were first detected in California, have been shown to be approximately 20% more transmissible than preexisting variants and have been classified by the CDC as variants of concern. The potential of variants to escape naturally induced and vaccine-induced immunity makes the development of next-generation vaccines that elicit broadly neutralizing activity against current and potential future variants a priority. The suppression of viral replication with both public health measures and the equitable distribution of vaccines is critical in reducing the risk of generation of new variants. Salim S. Abdool Karim, M.B., Ch.B., Ph.D. Centre for the AIDS Program of Research in South Africa, Durban, South Africa salim.abdoolkarim@caprisa.org Tulio de Oliveira, Ph.D. KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Durban, South Africa Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org. This letter was published on March 24, 2021, at NEJM.org. 1. . opens in new tab . opens in new tab 2. . opens in new tab . opens in new tab 3. . opens in new tab . opens in new tab 4. . opens in new tab . opens in new tab 5. . opens in new tab . opens in new tab Supplementary Material Supplementary Appendix PDF 134KB Disclosure Forms PDF 151KB Looks like global life expectancy is going to take a dip over the next decade. Growing older will be a early death sentence in of itself for some with this virus continuing to wreck havoc. For about 14% of others, long term disability. This is assuming no particularly nasty Covid variants emerge. Perhaps the Flu season in the Northern Hemisphere will become known as the annual purge, like the show, “The Purge”. Can someone please tell me we’ve learned our lesson for the next time a novel virus emerges, assuming the current one does not ultimately do us in? https://www.nejm.org/doi/full/10.1056/NEJMc2100362?query=featured_home
Assuming you mean these two vaccines The difference is one week -- in human time. How many weeks is that in Tony Stark time? FYI, Germany lost World War II, so Kalamazoo, Michigan, Groton, Connecticut, and McPherson, Kansas are not German cities.
Thank you President Trump!!! While Biden was hiding in his basement, you were doing what no one believed could be done. Thanks again for saving the world, 45!!!!
I don't think even Biden voters expected such swift deployment of the #BidenVaccine. Joe keeps surpassing expectations, even with insurmountable obstructionism from the party of domestic terrorists. https://www.webmd.com/vaccines/covi...-goal-is-200-million-vaccinations-in-100-days New Biden Goal: 200 Million Vaccinations in 100 Days Mar 26, 2021 -- On the day after the United States reported its 30 millionth coronavirus case, President Joe Biden announced a new vaccination goal. Speaking at his first formal news conference on Thursday, Biden predicted 200 million COVID-19 vaccination doses will be administered during the first 100 days of his administration. https://www.washingtonpost.com/health/2021/03/28/vaccine-passports-for-work/ ‘Vaccine passports’ are on the way, but developing them won’t be easy White House-led effort tries to corral more than a dozen initiatives The Biden administration and private companies are working to develop a standard way of handling credentials — often referred to as “vaccine passports” — that would allow Americans to prove they have been vaccinated against the novel coronavirus as businesses try to reopen. The effort has gained momentum amid President Biden’s pledge that the nation will start to regain normalcy this summer and with a growing number of companies — from cruise lines to sports teams — saying they will require proof of vaccination before opening their doors again.
Exactly on track as per Trumps plans....that everyone on the left, including Biden, mocked! Bravo President Trump!!!
I mean this vaccine https://fortune.com/2020/11/09/pfizer-vaccine-funding-warp-speed-germany/ It’s said that success has many authors, and the encouraging data from Pfizer Inc.’s experimental COVID-19 vaccine had plenty of people in Washington lining up to take credit. Vice President Mike Pence was among Trump administration officials saying support from the government’s Operation Warp Speed program helped accelerate the development of the vaccine, which was found to be more than 90% effective in preventing symptomatic COVID-19 infections in an interim analysis. The truth is that Pfizer didn’t receive any funding from Operation Warp Speed for the development, clinical trial and manufacturing of the vaccine. Rather, its partner, BioNTech SE, has received money -- from the German government. BioNTech is credited for contributing the messenger RNA technology, which prompts the body to make a key protein from the virus, creating an immune response. The biotechnology company already had a history of working with Pfizer on influenza vaccines, and in March they clinched a deal to co-develop a shot to prevent against COVID-19 at research sites both in the U.S. and Germany. The two companies began human testing of the vaccine in April, before the existence of Operation Warp Speed was revealed publicly. Berlin gave the German company $445 million in an agreement in September to help accelerate the vaccine by building out manufacturing and development capacity in its home market.
And yet more Americans have received Pfizer vax than Germans. Thank you President Trump and Operation Warp Speed!! Without your leadership this wouldn’t have been possible!!!
At least we are done with the Trump created the vaccine BS. Now on to Germany.Its an all around shit show that has notching to do with Trump.